Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

被引：0
作者：
Jun-ichi Kira
Yasuto Itoyama
Seiji Kikuchi
Qi Hao
Takayoshi Kurosawa
Kazuo Nagato
Isao Tsumiyama
Philipp von Rosenstiel
Lixin Zhang-Auberson
Takahiko Saida
机构：
[1] Kyushu University,Department of Neurology, Neurological Institute, Graduate School of Medical Sciences
[2] National Center of Neurology and Psychiatry,National Center Hospital
[3] National Hospital Organization,Hokkaido Medical Center
[4] Institute of Neurotherapeutics,Department of Neurology
[5] Novartis Pharma KK,undefined
[6] Mitsubishi Tanabe Pharma Corporation,undefined
[7] Novartis Pharma AG,undefined
[8] Kyoto Min-Iren-Central Hospital,undefined
[9] Kyoto University Hospital,undefined
来源：
BMC Neurology | / 14卷
关键词：
Aquaporin 4; Fingolimod; Longitudinally extensive spinal cord lesions; Multiple sclerosis; Phase 2 study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 119 条
[1]  
Brinkmann V(2010)Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 9 883-897
[2]  
Billich A(2010)Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 91-101
[3]  
Baumruker T(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
[4]  
Heining P(2006)Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 1124-1140
[5]  
Schmouder R(2010)A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 387-401
[6]  
Francis G(2012)A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis Mult Scler 18 1269-1277
[7]  
Aradhye S(2005)Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” Ann Neurol 58 840-846
[8]  
Burtin P(2010)Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results Mult Scler 16 197-207
[9]  
Chun J(2010)Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups Pharmacogenomics 11 781-791
[10]  
Hartung HP(2007)Genetic polymorphism in drug metabolism and toxicity: Linking animal research and risk assessment in man AATEX 14 443-445
12345678910